Pegfilgrastim-apgf - Biologic Drug Details

Summary for pegfilgrastim-apgf

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pegfilgrastim-apgf

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor Granulocyte-Macrophage Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim-apgf Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim-apgf Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pegfilgrastim-apgf Derived from Patent Text Search

No patents found based on company disclosures

Pegfilgrastim-apgf Market Analysis and Financial Projection

Last updated: February 13, 2026

What are the current market dynamics for pegfilgrastim-apgf?

Pegfilgrastim-apgf, marketed as Fulphila by Mylan (now part of Viatris), is a biosimilar to Neulasta (pegfilgrastim). It targets the prevention of febrile neutropenia in cancer patients undergoing chemotherapy. The biosimilar landscape has expanded, driven by patent expirations of originators like Amgen's Neulasta in 2021, prompting increased biosimilar entry.

Market penetration remains gradual but steady. According to IQVIA data, biosimilars accounted for approximately 15% of pegfilgrastim prescriptions in the U.S. in 2022, up from 8% in 2021. Market share gains are driven by cost advantages, with biosimilars priced 15-30% lower than the originator.

The global biologic market for neutropenia agents was valued at around $5 billion in 2022, with pegfilgrastim representing the largest segment. The expansion into markets such as Europe, Asia, and Latin America expands revenue potential. Price competition remains intense, with multiple biosimilars like Sandoz's Ziextenzo and Biogen's Fulphila competing in the same segments.

Reimbursement pathways in key regions influence adoption rates. In the U.S., Medicare formulary inclusion and pharmacy benefit managers (PBMs) negotiations affect biosimilar uptake. Some institutions prefer originator brands due to established efficacy perceptions but are gradually shifting as biosimilar data accumulates.

How does the financial trajectory look for pegfilgrastim-apgf?

Historically, Neulasta generated sales exceeding $3 billion annually before patent expiry. Post-exclusivity, sales declined sharply owing to biosimilar competition, with estimates showing a drop to approximately $1.5 billion in 2022.

Viatris projects biosimilar pegfilgrastim sales to grow compounded annually at around 15%, reaching roughly $3 billion globally by 2027. This hinges on increased market penetration, especially in non-U.S. territories and emerging markets.

Pricing strategies favor volume growth over per-unit margins; biosimilars tend to be priced at 15-30% below the originator. The company expects gross margins to compress from the high-20s percentage on originator sales to mid-teens or low 20s due to competitive pressures.

R&D expenses for biosimilars are primarily linked to regulatory pathways, manufacturing scale-up, and formulary negotiations. While initial R&D costs are high—approaching $100 million per biosimilar—these are amortized over sales cycles. Mylan/Viatris has an extensive biosimilar pipeline, which diversifies revenue streams and dilutes risk.

Despite increased competition, pegfilgrastim biosimilars are anticipated to sustain attractive margins, driven by cost efficiencies in manufacturing and regulatory approvals achieved in multiple jurisdictions. The price erosion rate for biosimilars in chemotherapeutic agents is estimated at 10-15% annually post-entry, making the product's financial trajectory sensitive to volume growth and market acceptance.

What are the regulatory and policy factors influencing market growth?

The U.S. FDA approved the biosimilar pegfilgrastim in 2018. The European Medicines Agency approved Fulphila in 2019, with subsequent approvals in Japan, Canada, and other regions. Regulatory acceptance accelerates market movement.

The pathway to biosimilar approval hinges on demonstrating similarity in efficacy, safety, and quality without requiring full clinical trials. As regulatory bodies approve more biosimilars and create favorable reimbursement policies, market penetration accelerates.

US policy discussions around automatic substitution at pharmacy level and tiered formulary access influence biosimilar adoption. The Centers for Medicare & Medicaid Services (CMS) incorporates biosimilar utilization metrics into reimbursement formulas, incentivizing switches.

Intellectual property disputes, patent thickets, and exclusivity periods impact market entry timing, but patent expirations are increasingly allowing biosimilar competition.

How do market competition and pricing strategies influence financial outcomes?

Price competition among biosimilar manufacturers keeps unit prices below originator levels. Multiple biosimilars entering the market pushes prices down further.

Manufacturers employ volume-based pricing models, offering discounts to large payers and health systems. Strategic bundling with chemotherapy regimens and inclusion in extended-care contracts enhance sales.

Pricing erosion of 10-15% annually is typical in this class, pressuring margins but potentially expanding total market volume. Firms leveraging manufacturing efficiencies and economies of scale can sustain profitability despite lower prices.

Market share gains depend on early adoption by payers and providers, favorable formulary decisions, and patient acceptance. Education around biosimilarity and interchangeability influences prescribing.

What are the key revenue drivers and constraints?

Key revenue drivers include:

• Market penetration in the U.S. and globally, especially in oncology centers adopting biosimilars.
• Competitive pricing that boosts volume.
• Expanded access in emerging markets with growing cancer treatment needs.
• Regulatory approvals in new regions, extending market reach.

Constraints stem from:

• Slow physician and patient acceptance due to brand loyalty and perceived efficacy.
• Price reductions eroding margins.
• Patent litigation delaying broader biosimilar uptake.
• Reimbursement challenges, particularly where originator products retain preferential coverage.

Closing Key Takeaways

• Pegfilgrastim-apgf faces increasing competition from multiple biosimilars, leading to pricing pressure and gradual market share gains.
• Global sales are projected to grow at roughly 15% annually, driven by expansion into new markets and increased biosimilar acceptance.
• Revenue will depend heavily on formulary inclusion, provider education, and payer policies.
• Margins are expected to compress as biosimilars undergo continuous price erosion; volume growth remains critical.
• Regulatory clarity and policies favoring biosimilar substitution will influence future growth trajectories.

5 FAQs

1. What is the primary advantage of pegfilgrastim biosimilars over the originator?
Lower price, approximately 15-30% below Neulasta, with comparable efficacy and safety.

2. How quickly can biosimilar pegfilgrastim capture market share?
Typically, within 3-5 years post-approval, market share can reach 20-30% in mature markets, contingent on payer acceptance and provider confidence.

3. Will pricing erosion continue?
Yes, biosimilars generally see 10-15% annual price declines following market entry.

4. Which regions offer the greatest growth potential?
Emerging markets like China, India, and Latin America, plus increased adoption in Europe and OECD countries.

5. What factors could accelerate biosimilar adoption?
Favorable regulatory policies, automatic substitution practices, and improved physician and patient education.

---

References

[1] IQVIA. (2022). Biosimilar Market Data.
[2] FDA. (2018). Approval of Fulphila.
[3] European Medicines Agency. (2019). EMA approvals for biosimilars.
[4] Center for Medicare & Medicaid Services. (2022). Policy on Biosimilar Utilization.
[5] EvaluatePharma. (2022). Biosimilar Market Projections.